Antibody Therapeutics (IF=4.5, published by Oxford University Press) Highlights
"The process using a synthetic library that generates multiple diverse human single domain antibodies" contributed by Mark A Tornetta from Tavotek Biotherapeutics.
academic.oup.com/abt/article/...
#Antibody #Therapeutics

"Connexin 43 hemichannels and related diseases"contributed by Yanfeng Zhang (AlaMab Therapeutics) and Jean X Jiang (University of Texas Health Science Center).
Free access of the full article through: academic.oup.com/abt/article/...
#Antibody #Therapeutics #mAbs

🚀 Insightful Review in Antibody Therapeutics(IF=4.5): Mapping the protein protein interactome in the tumor immune microenvironment
academic.oup.com/abt/article/...

Antibody Therapeutics, published by Oxford University Press, is proud to announce the award of its inaugural Impact Factor (4.5) by Clarivate Analytics in the latest Journal Citation Report (JCR)！
#Antibody #Therapeutics #ImpactFactor

New Publication Alert: "A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy" from Convalife Pharmaceuticals.
Free access of full text article through:https://academic.oup.com/abt/advance-article/doi/10.1093/abt/tbaf012/8140624
#Antibody #mAbs

New CiteScore Release: Antibody Therapeutics, published by Oxford University Press, is thrilled to announce that the newest CiteScore 2024 is 8.4. Thanks all the support from our readers, reviewers, editors, and editorial board members!